A Study of LY3415244 in Participants With Advanced Solid Tumors

Exclusion Criteria

• •Have symptomatic central nervous system (CNS) malignancy or metastasis not requiring concurrent treatment, including but not limited to surgery, radiation, corticosteroids and/or anticonvulsants to treat CNS metastases, and their disease is asymptomatic and radiographically stable for at least 30 days.
• •Have received a live vaccine within 30 days before the first dose of study treatment.
• •If female, is pregnant, breastfeeding, or planning to become pregnant.
• •Have a history or current evidence of any condition, therapy, or laboratory abnormality that might interfere with the participant's participation.
• •Have moderate or severe cardiovascular disease.
• •Have a serious concomitant systemic disorder that would compromise the participant's ability to adhere to the protocol, including known infection with human immunodeficiency virus (HIV), active hepatitis B virus (HBV), active hepatitis C virus (HCV), active autoimmune disorders, or prior documented severe autoimmune or inflammatory disorders requiring immunosuppressive treatment.
• •Use of escalating or chronic supraphysiologic doses of corticosteroids or immunosuppressive agents (such as, cyclosporine). \[Use of topical, ophthalmic, inhaled, and intranasal corticosteroids permitted\].
• •Bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection.
• •Evidence of interstitial lung disease or noninfectious pneumonitis.